bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

2.860 -0.100 (-3.38%)

Delayed Quote Updated: 11:30 AM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Are Pharma Stocks Harmful To Your Financial Health ? ↗

October 09, 2024

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.

Via Talk Markets

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

October 09, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

August 23, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

September 18, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024 ↗

August 14, 2024

bioAffinity Technologies just reported results for the second quarter of 2024.

Via InvestorPlace

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

August 14, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

August 05, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views ↗

August 02, 2024

Via Benzinga

Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July ↗

August 02, 2024

Via Benzinga

Topics Economy

Dow Dips Over 400 Points; Apple Posts Upbeat Earnings ↗

August 02, 2024

Via Benzinga

Topics Stocks

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

August 02, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 12, 2024

Via ACCESSWIRE

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

July 09, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 05, 2024

Via ACCESSWIRE

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

June 12, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024 ↗

May 15, 2024

bioAffinity Technologies just reported results for the first quarter of 2024.

Via InvestorPlace

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

May 15, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies News Update

May 02, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

April 24, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

April 09, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 05, 2024

Via Benzinga

BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023 ↗

April 01, 2024

bioAffinity Technologies just reported results for the fourth quarter of 2023.

Via InvestorPlace

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

April 01, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 11, 2024

Via Benzinga

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 11, 2024

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart...

Via Benzinga

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

March 08, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Nasdaq Gains 100 Points; Campbell Soup Earnings Top Views ↗

March 06, 2024

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The...

Via Benzinga

Topics Stocks

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 06, 2024

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 06, 2024

Via Benzinga

Why BioAffinity Technologies (BIAF) Shares Are Down 50% ↗

March 06, 2024

BioAffinity Technologies shares are trading lower by 50.7% during Wednesday's session. The company announced a securities purchase agreement with institutional investors.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.